Logo image of CR

CRANE CO (CR) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:CR - US2244081046 - Common Stock

207.42 USD
+0.51 (+0.25%)
Last: 1/16/2026, 8:04:00 PM
207.42 USD
0 (0%)
After Hours: 1/16/2026, 8:04:00 PM
Fundamental Rating

7

Overall CR gets a fundamental rating of 7 out of 10. We evaluated CR against 132 industry peers in the Machinery industry. Both the health and profitability get an excellent rating, making CR a very profitable company, without any liquidiy or solvency issues. CR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • CR had positive earnings in the past year.
  • In the past year CR had a positive cash flow from operations.
  • Each year in the past 5 years CR has been profitable.
  • Of the past 5 years CR 4 years had a positive operating cash flow.
CR Yearly Net Income VS EBIT VS OCF VS FCFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • With an excellent Return On Assets value of 14.35%, CR belongs to the best of the industry, outperforming 92.42% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 18.61%, CR belongs to the top of the industry, outperforming 82.58% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 13.88%, CR belongs to the best of the industry, outperforming 82.58% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CR is in line with the industry average of 10.24%.
  • The last Return On Invested Capital (13.88%) for CR is above the 3 year average (9.11%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.35%
ROE 18.61%
ROIC 13.88%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
CR Yearly ROA, ROE, ROICCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • CR has a better Profit Margin (17.33%) than 92.42% of its industry peers.
  • In the last couple of years the Profit Margin of CR has grown nicely.
  • CR has a better Operating Margin (18.33%) than 84.85% of its industry peers.
  • In the last couple of years the Operating Margin of CR has grown nicely.
  • CR has a better Gross Margin (43.41%) than 81.06% of its industry peers.
  • In the last couple of years the Gross Margin of CR has grown nicely.
Industry RankSector Rank
OM 18.33%
PM (TTM) 17.33%
GM 43.41%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
CR Yearly Profit, Operating, Gross MarginsCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

9

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CR is still creating some value.
  • Compared to 1 year ago, CR has more shares outstanding
  • Compared to 5 years ago, CR has less shares outstanding
  • The debt/assets ratio for CR has been reduced compared to a year ago.
CR Yearly Shares OutstandingCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CR Yearly Total Debt VS Total AssetsCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 14.85 indicates that CR is not in any danger for bankruptcy at the moment.
  • CR has a Altman-Z score of 14.85. This is amongst the best in the industry. CR outperforms 94.70% of its industry peers.
  • CR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 14.85
ROIC/WACC1.41
WACC9.81%
CR Yearly LT Debt VS Equity VS FCFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • CR has a Current Ratio of 3.27. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
  • CR has a Current ratio of 3.27. This is amongst the best in the industry. CR outperforms 82.58% of its industry peers.
  • A Quick Ratio of 2.26 indicates that CR has no problem at all paying its short term obligations.
  • CR has a Quick ratio of 2.26. This is amongst the best in the industry. CR outperforms 80.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.27
Quick Ratio 2.26
CR Yearly Current Assets VS Current LiabilitesCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.21% over the past year.
  • The Earnings Per Share has been decreasing by -3.00% on average over the past years.
  • Looking at the last year, CR shows a decrease in Revenue. The Revenue has decreased by -7.25% in the last year.
  • Measured over the past years, CR shows a decrease in Revenue. The Revenue has been decreasing by -8.28% on average per year.
EPS 1Y (TTM)20.21%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%18.84%
Revenue 1Y (TTM)-7.25%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.34%

3.2 Future

  • CR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
  • The Revenue is expected to grow by 6.48% on average over the next years.
EPS Next Y18.11%
EPS Next 2Y14.84%
EPS Next 3Y13.91%
EPS Next 5Y12.63%
Revenue Next Year7.02%
Revenue Next 2Y6.86%
Revenue Next 3Y6.7%
Revenue Next 5Y6.48%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CR Yearly Revenue VS EstimatesCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
CR Yearly EPS VS EstimatesCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6 8

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 35.95 indicates a quite expensive valuation of CR.
  • Based on the Price/Earnings ratio, CR is valued a bit more expensive than 62.88% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of CR to the average of the S&P500 Index (27.38), we can say CR is valued slightly more expensively.
  • With a Price/Forward Earnings ratio of 30.48, CR can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, CR is valued a bit more expensive than 62.88% of the companies in the same industry.
  • CR's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.29.
Industry RankSector Rank
PE 35.95
Fwd PE 30.48
CR Price Earnings VS Forward Price EarningsCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CR is valued a bit more expensive than 69.70% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CR is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.58
EV/EBITDA 26.56
CR Per share dataCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CR does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of CR may justify a higher PE ratio.
  • CR's earnings are expected to grow with 13.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.98
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y13.91%

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.44%, CR is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.98, CR has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.85, CR's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.44%

5.2 History

  • The dividend of CR decreases each year by -12.19%.
  • CR has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-12.19%
Div Incr Years0
Div Non Decr Years0
CR Yearly Dividends per shareCR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • CR pays out 14.07% of its income as dividend. This is a sustainable payout ratio.
DP14.07%
EPS Next 2Y14.84%
EPS Next 3Y13.91%
CR Yearly Income VS Free CF VS DividendCR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M
CR Dividend Payout.CR Dividend Payout, showing the Payout Ratio.CR Dividend Payout.PayoutRetained Earnings

CRANE CO

NYSE:CR (1/16/2026, 8:04:00 PM)

After market: 207.42 0 (0%)

207.42

+0.51 (+0.25%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)10-27
Earnings (Next)01-26
Inst Owners77.23%
Inst Owner Change0%
Ins Owners0.27%
Ins Owner Change-0.16%
Market Cap11.95B
Revenue(TTM)2.11B
Net Income(TTM)365.90M
Analysts83.33
Price Target218.68 (5.43%)
Short Float %1.09%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield 0.44%
Yearly Dividend0.82
Dividend Growth(5Y)-12.19%
DP14.07%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.41%
Min EPS beat(2)7.02%
Max EPS beat(2)7.79%
EPS beat(4)4
Avg EPS beat(4)4.58%
Min EPS beat(4)0.24%
Max EPS beat(4)7.79%
EPS beat(8)8
Avg EPS beat(8)4.11%
EPS beat(12)12
Avg EPS beat(12)9.6%
EPS beat(16)15
Avg EPS beat(16)7.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.24%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-1.18%
Revenue beat(4)0
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-1.29%
Max Revenue beat(4)-1.07%
Revenue beat(8)1
Avg Revenue beat(8)-1.01%
Revenue beat(12)3
Avg Revenue beat(12)-4.21%
Revenue beat(16)5
Avg Revenue beat(16)-0.03%
PT rev (1m)0.42%
PT rev (3m)1.71%
EPS NQ rev (1m)0.2%
EPS NQ rev (3m)-0.62%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.54%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.13%
Valuation
Industry RankSector Rank
PE 35.95
Fwd PE 30.48
P/S 5.66
P/FCF 21.58
P/OCF 19.64
P/B 6.08
P/tB 10.58
EV/EBITDA 26.56
EPS(TTM)5.77
EY2.78%
EPS(NY)6.81
Fwd EY3.28%
FCF(TTM)9.61
FCFY4.63%
OCF(TTM)10.56
OCFY5.09%
SpS36.66
BVpS34.14
TBVpS19.61
PEG (NY)1.98
PEG (5Y)N/A
Graham Number66.57
Profitability
Industry RankSector Rank
ROA 14.35%
ROE 18.61%
ROCE 17.94%
ROIC 13.88%
ROICexc 16.92%
ROICexgc 32.12%
OM 18.33%
PM (TTM) 17.33%
GM 43.41%
FCFM 26.22%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
ROICexc(3y)10.78%
ROICexc(5y)10.01%
ROICexgc(3y)18.74%
ROICexgc(5y)19.36%
ROCE(3y)12.01%
ROCE(5y)11.18%
ROICexgc growth 3Y10.29%
ROICexgc growth 5Y0.39%
ROICexc growth 3Y13.04%
ROICexc growth 5Y6.99%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 113.69%
Cap/Sales 2.6%
Interest Coverage 30
Cash Conversion 139.8%
Profit Quality 151.3%
Current Ratio 3.27
Quick Ratio 2.26
Altman-Z 14.85
F-Score8
WACC9.81%
ROIC/WACC1.41
Cap/Depr(3y)93.58%
Cap/Depr(5y)79.88%
Cap/Sales(3y)1.9%
Cap/Sales(5y)1.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.21%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%18.84%
EPS Next Y18.11%
EPS Next 2Y14.84%
EPS Next 3Y13.91%
EPS Next 5Y12.63%
Revenue 1Y (TTM)-7.25%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.34%
Revenue Next Year7.02%
Revenue Next 2Y6.86%
Revenue Next 3Y6.7%
Revenue Next 5Y6.48%
EBIT growth 1Y8.07%
EBIT growth 3Y17.08%
EBIT growth 5Y-5.09%
EBIT Next Year26.63%
EBIT Next 3Y16.69%
EBIT Next 5Y13.57%
FCF growth 1Y219.08%
FCF growth 3Y-20.47%
FCF growth 5Y-6.44%
OCF growth 1Y182.06%
OCF growth 3Y-18.53%
OCF growth 5Y-7.3%

CRANE CO / CR FAQ

What is the fundamental rating for CR stock?

ChartMill assigns a fundamental rating of 7 / 10 to CR.


Can you provide the valuation status for CRANE CO?

ChartMill assigns a valuation rating of 2 / 10 to CRANE CO (CR). This can be considered as Overvalued.


Can you provide the profitability details for CRANE CO?

CRANE CO (CR) has a profitability rating of 9 / 10.


Can you provide the expected EPS growth for CR stock?

The Earnings per Share (EPS) of CRANE CO (CR) is expected to grow by 18.11% in the next year.


How sustainable is the dividend of CRANE CO (CR) stock?

The dividend rating of CRANE CO (CR) is 3 / 10 and the dividend payout ratio is 14.07%.